Does Lithium Prevent Alzheimer's Disease?


Autoria(s): Forlenza, Orestes V.; de Paula, Vanessa J.; Machado-Vieira, Rodrigo; Diniz, Breno S.; Gattaz, Wagner F.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

29/10/2013

29/10/2013

2012

Resumo

Lithium salts have a well-established role in the treatment of major affective disorders. More recently, experimental and clinical studies have provided evidence that lithium may also exert neuroprotective effects. In animal and cell culture models, lithium has been shown to increase neuronal viability through a combination of mechanisms that includes the inhibition of apoptosis, regulation of autophagy, increased mitochondrial function, and synthesis of neurotrophic factors. In humans, lithium treatment has been associated with humoral and structural evidence of neuroprotection, such as increased expression of anti-apoptotic genes, inhibition of cellular oxidative stress, synthesis of brain-derived neurotrophic factor (BDNF), cortical thickening, increased grey matter density, and hippocampal enlargement. Recent studies addressing the inhibition of glycogen synthase kinase-3 beta (GSK3B) by lithium have further suggested the modification of biological cascades that pertain to the pathophysiology of Alzheimer's disease (AD). A recent placebo-controlled clinical trial in patients with amnestic mild cognitive impairment (MCI) showed that long-term lithium treatment may actually slow the progression of cognitive and functional deficits, and also attenuate Tau hyperphosphorylation in the MCI-AD continuum. Therefore, lithium treatment may yield disease-modifying effects in AD, both by the specific modification of its pathophysiology via inhibition of overactive GSK3B, and by the unspecific provision of neurotrophic and neuroprotective support. Although the clinical evidence available so far is promising, further experimentation and replication of the evidence in large scale clinical trials is still required to assess the benefit of lithium in the treatment or prevention of cognitive decline in the elderly.

Conselho Nacional de Pesquisa Cientifica (CNPq)

Conselho Nacional de Pesquisa Cientifica (CNPq) [554535/2005-0]

Alzheimer's Association [NIRG-08-90688]

Alzheimers Association

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [02/13635-7, 09/52825-8]

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Associacao Beneficente Alzira Denise Hertzog da Silva (ABADHS)

Associacao Beneficente Alzira Denise Hertzog da Silva (ABADHS)

Identificador

DRUGS & AGING, AUCKLAND, v. 29, n. 5, supl. 1, Part 2, pp. 335-342, AUG, 2012

1170-229X

http://www.producao.usp.br/handle/BDPI/36234

10.2165/11599180-000000000-00000

http://dx.doi.org/10.2165/11599180-000000000-00000

Idioma(s)

eng

Publicador

ADIS INT LTD

AUCKLAND

Relação

DRUGS & AGING

Direitos

closedAccess

Copyright ADIS INT LTD

Palavras-Chave #AMYOTROPHIC-LATERAL-SCLEROSIS #GLYCOGEN-SYNTHASE KINASE-3 #ANTIDEPRESSANT-FREE PATIENTS #EUTHYMIC BIPOLAR PATIENTS #LATE-LIFE DEPRESSION #N-ACETYL-ASPARTATE #NEUROTROPHIC FACTOR #HUNTINGTONS-DISEASE #CORTICAL-NEURONS #DRINKING-WATER #GERIATRICS & GERONTOLOGY #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion